12:00 AM
Aug 02, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

NX-1207: Advisory committee approval

Nymox said a safety monitoring committee recommended continuation of a pair of double-blind, placebo controlled, U.S. Phase III trials evaluating a...

Read the full 85 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >